Two 59%+ winners, four above 25% in Aug – How this AI model keeps picking winners
NEW YORK - Elanco Animal Health Inc. (NYSE:ELAN) reported better-than-expected first quarter results and raised its full-year revenue guidance on Wednesday.
The company’s shares jumped 3.47% in premarket trading following the release.
The animal health company posted adjusted earnings per share of $0.37, beating analyst estimates of $0.31. Revenue came in at $1.19 billion, topping expectations of $1.17 billion.
Elanco saw organic constant currency revenue growth of 4% in the quarter, driven by strength in its Farm Animal segment. Pet Health revenue was flat on an organic basis.
"Elanco exceeded first quarter guidance for revenue, adjusted EBITDA, and adjusted EPS," said CEO Jeff Simmons. "Our diverse portfolio delivered 4% organic constant currency revenue growth, with accelerating Pet Health trends in March and April, and consistently strong execution in Farm Animal."
For the full year 2025, Elanco raised its revenue guidance to $4.51-$4.58 billion, up from its previous outlook of $4.45-$4.51 billion and above analyst projections of $4.5 billion. The company maintained its adjusted EPS forecast of $0.80-$0.86.
Elanco cited a favorable foreign exchange tailwind of $65-$70 million for the improved revenue outlook. It continues to expect mid-single digit organic constant currency revenue growth for the year.
The company now targets ending 2025 with a net leverage ratio of 3.9x to 4.3x, an improvement from its prior goal, enabled by disciplined working capital management and more favorable foreign exchange rates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.